STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13D/A] GoHealth, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

Amendment No. 5 to the Schedule 13D discloses a Superpriority Senior Secured Term Loan package totaling $115.0 million for Norvax, LLC, comprised of $80.0 million new-money term loans (with $40.0 million funded immediately and $40.0 million as delayed-draw availability) and $35.0 million of roll-up term loans from conversion of existing Class A revolving loans.

The related amendment to the existing credit agreement terminates Class A-1 and Class A revolving commitments, extends the maturity of remaining Class A revolving loans to August 5, 2029, permits pay-in-kind interest with an accrual rate of Adjusted Term SOFR + 8.00% (with at least Adjusted Term SOFR + 4.50% paid in cash), and waives amortization of existing term loans until December 31, 2026. As consideration, the issuer issued 4,766,219 Class A shares to certain lenders, representing 19.99% of the combined issued and outstanding Class A and Class B common stock, with customary registration rights. The Board appointed three new directors and three existing directors resigned.

Reporting Persons disclose beneficial ownership stakes in Class A common stock: CCP III Cayman GP Ltd. 9,566,028 shares (45.0%), CB Blizzard Holdings C 1,467,653 shares (9.2%), Centerbridge Associates III, L.P. and related entities 2,712,197 shares (17.1%), Blizzard Aggregator, LLC 5,386,178 shares (25.3%), and Jeffrey H. Aronson 9,566,028 shares (45.0%). The filing states the group may be deemed to collectively beneficially own 16,007,486 shares, approximately 58.3% of 15,881,344 reported Class A shares outstanding.

Positive
  • $115.0 million superpriority facility provides immediate liquidity through a mix of new-money term loans and roll-up of existing revolver exposure
  • Delayed-draw structure allows the borrower to access an additional $40.0 million in staged amounts, with explicit availability caps prior to full funding
  • Issuance of 4,766,219 subscription shares includes customary registration rights, which may facilitate eventual public liquidity for those shares
  • Amendment removes certain restrictive covenants and extends maturity of remaining revolver loans to August 5, 2029, creating near-term flexibility
Negative
  • Lenders received equity equal to 19.99% of combined Class A and B stock, representing material dilution to existing shareholders
  • The superpriority loan accrues interest at Adjusted Term SOFR + 8.00% with a pay-in-kind component, increasing the effective cost of capital
  • Priming loan's superpriority status changes creditor recovery priorities and may subordinate existing claimants unless otherwise addressed
  • Board composition changed with three directors appointed and three resignations, representing a material governance shift

Insights

TL;DR: Credit priming and equity issuance materially alter capital structure and dilute public holders while providing near-term liquidity.

The priming facility and Amendment restructure the borrower’s secured debt by creating a superpriority tranche and converting existing revolver exposure into term debt, delivering $115.0 million of incremental secured financing. The economics are costly: interest accrues at Adjusted Term SOFR + 8.00% with a substantial pay-in-kind component, and amortization is waived until 2026. Lenders received 4,766,219 subscription shares equal to 19.99% of combined Class A/B stock, which is significant dilution. For minority public holders this increases secured creditor recoveries ahead of existing claims and dilutes equity stakes; however, it also supplies immediate liquidity that may avert more disruptive outcomes.

TL;DR: Transaction is materially impactful; it secures additional funding and governance changes enabling creditor-lender alignment.

The combination of a superpriority priming loan, roll-up of existing revolver debt and issuance of equity to lenders represents a comprehensive recapitalization step. Term and covenant modifications, including removal of certain covenants and extended maturities, create breathing room for operations and potential strategic options. Board composition changes tied to the transactions align governance with consenting creditors. These features make the transaction highly material to stakeholders and likely to influence future restructuring or strategic outcomes.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


CCP III Cayman GP Ltd.
Signature:/s/ Susanne V. Clark
Name/Title:Susanne V. Clark/Authorized Signatory
Date:08/08/2025
CB Blizzard Holdings C, L.P.
Signature:By: CCP III Cayman GP Ltd., its general partner, /s/ Susanne V. Clark
Name/Title:Susanne V. Clark/Authorized Signatory
Date:08/08/2025
Centerbridge Associates III, L.P.
Signature:By: CCP III Cayman GP Ltd., its general partner, /s/ Susanne V. Clark
Name/Title:Susanne V. Clark/Authorized Signatory
Date:08/08/2025
CCP III AIV VII Holdings, L.P.
Signature:By: Centerbridge Associates III, L.P., its general partner, By: CCP III Cayman GP Ltd., its general partner, /s/ Susanne V. Clark
Name/Title:Susanne V. Clark/Authorized Signatory
Date:08/08/2025
CB Blizzard Co-Invest Holdings, L.P.
Signature:By: Centerbridge Associates III, L.P., its general partner, By: CCP III Cayman GP Ltd., its general partner, /s/ Susanne V. Clark
Name/Title:Susanne V. Clark/Authorized Signatory
Date:08/08/2025
CB Blizzard Lower Holdings GP A, LLC
Signature:/s/ Susanne V. Clark
Name/Title:Susanne V. Clark/Authorized Signatory
Date:08/08/2025
CB Blizzard Lower Holdings A, L.P.
Signature:By: CB Blizzard Lower Holdings GP A, LLC, its general partner, /s/ Susanne V. Clark
Name/Title:Susanne V. Clark/Authorized Signatory
Date:08/08/2025
Blizzard Aggregator, LLC
Signature:By: CCP III Cayman GP Ltd., its sole manager, /s/ Susanne V. Clark
Name/Title:Susanne V. Clark/Authorized Signatory
Date:08/08/2025
CB Blizzard Lower Holdings GP B, LLC
Signature:/s/ Susanne V. Clark
Name/Title:Susanne V. Clark/Authorized Signatory
Date:08/08/2025
CB Blizzard Lower Holdings B, L.P.
Signature:By: CB Blizzard Lower Holdings GP B, LLC, its general partner, /s/ Susanne V. Clark
Name/Title:Susanne V. Clark/Authorized Signatory
Date:08/08/2025
Jeffrey H. Aronson
Signature:/s/ Jeffrey H. Aronson
Name/Title:Jeffrey H. Aronson
Date:08/08/2025

FAQ

What financing did GoHealth (GOCO) obtain in this Schedule 13D/A?

The filing discloses a $115.0 million Superpriority Senior Secured term loan facility: $80.0 million new-money term loans (with $40.0 million funded immediately and $40.0 million delayed-draw) and $35.0 million of roll-up term loans.

How many shares were issued to lenders and what dilution does that cause?

The issuer issued 4,766,219 Class A shares to certain lenders, representing 19.99% of the combined issued and outstanding Class A and Class B common stock as stated in the filing.

What are the reported beneficial ownership stakes for the Reporting Persons (GOCO)?

Reported stakes include CCP III Cayman GP Ltd. 9,566,028 shares (45.0%), CB Blizzard Holdings C 1,467,653 shares (9.2%), Centerbridge Associates III and related entities 2,712,197 shares (17.1%), Blizzard Aggregator, LLC 5,386,178 shares (25.3%), and Jeffrey H. Aronson 9,566,028 shares (45.0%).

What material changes to the credit agreement were made?

The Amendment terminates Class A-1 and Class A revolving commitments, extends maturity of remaining Class A revolving loans to August 5, 2029, permits pay-in-kind interest with accrual at Adjusted Term SOFR + 8.00%, and waives amortization of existing term loans until December 31, 2026.

Were there governance changes disclosed in the filing?

Yes. The Board appointed three new directors and three existing directors resigned; two of the departing directors were previously designated by Centerbridge.
Gohealth, Inc.

NASDAQ:GOCO

GOCO Rankings

GOCO Latest News

GOCO Latest SEC Filings

GOCO Stock Data

37.01M
9.37M
15.64%
60.62%
1.04%
Insurance Brokers
Insurance Agents, Brokers & Service
Link
United States
CHICAGO